Oak Ridge Investments LLC purchased a new position in shares of Bristol-Myers Squibb Co (NYSE:BMY) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 115,002 shares of the biopharmaceutical company’s stock, valued at approximately $6,410,000.

Other institutional investors have also bought and sold shares of the company. Orser Capital Management LLC boosted its holdings in shares of Bristol-Myers Squibb by 78.9% during the fourth quarter. Orser Capital Management LLC now owns 5,010 shares of the biopharmaceutical company’s stock worth $319,000 after acquiring an additional 2,210 shares during the period. Koshinski Asset Management Inc. bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $375,000. Parallel Advisors LLC boosted its holdings in shares of Bristol-Myers Squibb by 29.1% during the fourth quarter. Parallel Advisors LLC now owns 27,935 shares of the biopharmaceutical company’s stock worth $1,793,000 after acquiring an additional 6,298 shares during the period. Savant Capital LLC boosted its holdings in shares of Bristol-Myers Squibb by 25.4% during the fourth quarter. Savant Capital LLC now owns 13,128 shares of the biopharmaceutical company’s stock worth $843,000 after acquiring an additional 2,658 shares during the period. Finally, GWM Advisors LLC boosted its holdings in shares of Bristol-Myers Squibb by 122.9% during the fourth quarter. GWM Advisors LLC now owns 76,435 shares of the biopharmaceutical company’s stock worth $4,906,000 after acquiring an additional 42,151 shares during the period. Institutional investors and hedge funds own 74.17% of the company’s stock.

Shares of NYSE:BMY traded down $0.45 during trading on Wednesday, hitting $60.20. 8,590,384 shares of the company were exchanged, compared to its average volume of 16,279,821. The business’s 50 day moving average is $61.21 and its 200-day moving average is $60.87. The company has a market capitalization of $136.42 billion, a P/E ratio of 74.30, a price-to-earnings-growth ratio of 1.17 and a beta of 0.72. The company has a quick ratio of 1.51, a current ratio of 1.66 and a debt-to-equity ratio of 0.86. Bristol-Myers Squibb Co has a 1-year low of $42.48 and a 1-year high of $68.34.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.23. The company had revenue of $10.78 billion during the quarter, compared to the consensus estimate of $10.04 billion. Bristol-Myers Squibb had a net margin of 3.08% and a return on equity of 30.06%. The company’s revenue for the quarter was up 82.1% compared to the same quarter last year. During the same period in the prior year, the business earned $1.10 earnings per share. As a group, sell-side analysts anticipate that Bristol-Myers Squibb Co will post 6.15 earnings per share for the current year.

In related news, EVP Louis S. Schmukler sold 25,000 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $62.68, for a total value of $1,567,000.00. Following the sale, the executive vice president now owns 26,777 shares of the company’s stock, valued at $1,678,382.36. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Adam Dubow sold 3,200 shares of the business’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $61.01, for a total transaction of $195,232.00. Following the completion of the sale, the senior vice president now directly owns 16,086 shares in the company, valued at approximately $981,406.86. The disclosure for this sale can be found here. 0.14% of the stock is currently owned by corporate insiders.

A number of brokerages have recently issued reports on BMY. Zacks Investment Research cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $66.00 price objective for the company. in a report on Thursday, April 16th. William Blair reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research report on Monday. ValuEngine downgraded shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Monday. Morgan Stanley upgraded shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and set a $64.00 price target for the company in a research report on Thursday, April 2nd. Finally, Barclays began coverage on shares of Bristol-Myers Squibb in a research report on Thursday, February 27th. They issued an “equal weight” rating and a $69.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $68.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: Catch-Up Contributions

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.